Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16039791 | 1.00 | KDM4E (0.37) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| SCHEMBL16038869 | 0.99 | HCAR2 (0.36) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| SCHEMBL16038868 | 0.99 | HCAR2 (0.36) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| Hydrochloric Acid SCHEMBL15512408 | 0.92 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| Hydrochloric Acid SCHEMBL15512407 | 0.92 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| SCHEMBL15512770 | 0.90 | KDM4E (0.39) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| SCHEMBL15499958 | 0.90 | KDM4E (0.39) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| Hydrochloric Acid SCHEMBL28392698 | 0.85 | ATM (0.39) | HCAR2HRH3ATMCYP2D6SLC6A4 | |
| SCHEMBL20220658 | 0.83 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDHCAR2KEAP1 | |
| SCHEMBL28392778 | 0.83 | ATM (0.40) | HCAR2HRH3ATMCYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| EP-2970101-B2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-24 | — | — | US | disclosed |
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-02-20 | — | — | US | disclosed |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-09-03 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| US-20220257520-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2022-08-18 | — | — | US | disclosed |
| US-20180064673-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-02-15 | — | — | US | disclosed |
| US-9775823-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-10-03 | — | — | US | disclosed |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-04-06 | — | — | US | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| WO-2016124960-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-08-11 | — | — | WO | disclosed |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2970101-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152494-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20220257520-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | DHFR, FPGS, G6PD | HRH3 2702/4885HTR2A 1913/4885HTR2C 1775/4885 |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | DHFR, FPGS, G6PD | HRH3 2702/4885HTR2A 1913/4885HTR2C 1775/4885 |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | DHFR, FPGS, G6PD | HRH3 2702/4885HTR2A 1913/4885HTR2C 1775/4885 |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20180064673-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HRH3 3716/4885HTR2A 3734/4885HTR2C 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.